Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NextGen ID Cap System for Medication Adherence
NCT05592613Phase 3Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Feb 2023
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
Phase 3, open-label trial (2 arms), sponsored by Brigham and Women's Hospital. Primary endpoints: Feasibility of Next-Generation ID-Cap System to Measure PrEP/ART Adherence at Month 1, Correlation of PrEP/ART Adherence with DBS Concentrations and Pill Counts at Month 1 and 2 more. Started Feb 2023; status: completed.
Beyond the preview
Go deeper on NCT05592613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05592613.